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Background. Disciplines involved in diagnosing transfusion-related acute lung injury (TRALI) 
report according to a "one-hit" theory. However, studies showed that patients with an underlying 
condition are at increased risk of the development of TRALI. We investigated whether accumulating 
evidence on the "two-hit" theory has changed the practice of reporting TRALI. 
Materials and methods. Departments of haematology, haemovigilance, transfusion medicine, 
intensive care and anaesthesiology from all Dutch hospitals with at least five beds equipped for 
mechanical ventilation were invited to participate in an online survey. Using clinical vignettes with 
conjoint analysis we investigated the effect of patients' age, admission diagnosis, type and number 
of transfusions and presence of risk factors for acute lung injury on TRALI reporting. A positive 
b-coefficient indicated a higher likelihood of reporting TRALI. 
Results. We received 129 questionnaires (response rate 74%). Respondents were more likely 
to report TRALI in younger patients, if symptoms developed within 2 hours of transfusion and if 
patients had received multiple transfusions. Sepsis and the presence of a risk factor for acute lung 
injury reduced the inclination to report. Transfusion medicine physicians and haemovigilance staff no 
longer took the age of transfusion products into account in their diagnostic considerations on TRALI. 
Discussion. We conclude that the multidisciplinary team involved in TRALI reporting, still 
considers TRALI a "one-hit" event, despite accumulating evidence that supports the "two-hit" 
theory. These results suggest that the patients most at risk of developing TRALI are not reported to 
the blood bank.
Keywords: haemovigilance, reporting, transfusion-related acute lung injury, two-hit model, 
vignette study.
Introduction
Transfusion-related acute lung injury (TRALI) is 
a respiratory syndrome caused by blood transfusion. 
Patients suffer symptoms of dyspnoea, fever, 
hypotension or sometimes hypertension, and hypoxia. 
In the absence of biomarkers, TRALI is a clinically 
diagnosed syndrome and is defined as new acute lung 
injury (ALI) developing within 6 hours of receiving a 
blood transfusion (Table I). Possible TRALI has the 
same definition, but in these cases other risk factors for 
ALI are also present1-4. Approximately 80% of TRALI 
cases have been related to the presence of antibodies to 
human leucocyte antigens or human neutrophil antigens, 
predominantly in female donor blood5,6. 
The reported incidence of TRALI varies widely, 
ranging from 0.0008 to 1.2% per blood product and 
from 0.08 to 8% per transfused patient7. This 100- to 
1000-fold difference in incidences can be explained 
by differences in study design and patient population 
but also by underreporting by treating physicians8-10. A 
study in which 36 recipients of a transfusion product 
from a donor implicated in TRALI were retraced, 
identified 15 TRALI reactions of which only seven 
were reported in the hospital and none was reported 
to the Blood Bank11.
A multidisciplinary team is usually involved in 
reporting TRALI. The bedside physician reports 
a TRALI case to the hospital's haemovigilance 
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representative. In turn, the haemovigilance officer 
reports the case to a transfusion medicine specialist at 
the national Sanquin Blood Bank. Reports of TRALI 
are important for identifying and excluding involved 
donors with antibodies in order to prevent future TRALI 
reactions. In 2008 a survey was conducted to identify 
what factors influenced reporting of TRALI. This 
survey showed that the presence of sepsis was a reason 
for not reporting TRALI. This indicates that physicians 
suspect TRALI according to the "single-hit" theory, in 
which antibodies in donor plasma are thought to induce 
activation of the pulmonary neutrophils in the absence of 
a priming "first-hit". However, studies in the past decade 
have indicated that even though TRALI can occur after 
a "single hit", for example in response to a transfusion 
product with high levels of cognate antigens (threshold 
model)12, it usually follows a "two-hit" model in which 
a clinical condition (e.g., sepsis, cardiac surgery) primes 
neutrophils. The "second hit", formed by the transfusion 
products, activates primed neutrophils and causes 
TRALI13-22. In this follow-up study we investigated 
whether the improved knowledge on the pathogenesis 
of TRALI has induced a shift in focus from reporting 
TRALI according to the "single-hit" theory to the "two-
hit"-model among anaesthesiologists, haematologists, 
intensive care physicians, haemovigilance staff and 
transfusion physicians. Moreover, we investigated 
whether the introduction of TRALI mitigation strategies, 
such as male only plasma and pooled plasma, has 
influenced TRALI reporting. 
Materials and methods
Potential participants
We used an e-mail invitation to request participation 
in our online survey. We contacted the heads of the 
department of intensive care medicine, haematology, 
anaesthesiology and haemovigilance of all Dutch 
hospitals with five or more beds equipped for mechanical 
ventilation in their intensive care units (n=68). The 
chairs of the departments that were willing to participate 
provided the name and e-mail address of the intensivist, 
haematologist, anaesthesiologist or haemovigilance 
officer who was most experienced with transfusion 
medicine. All transfusion physicians of Sanquin blood 
supply were also invited to participate (n=23). 
Survey
The survey was sent out with Survey Monkey, a web-
based survey programme (Survey Monkey, Palo Alto, 
CA, USA). The first part of the survey inventoried basic 
demographic characteristics: sex, age, specialisation, 
work experience, academic- or non-academic hospital 
setting and, for non-physicians, educational background. 
This was followed by 16 vignettes and 10 questions on 
additional factors influencing TRALI reporting. The 
survey was introduced with a cover letter providing 
the definition of TRALI according to the Canadian 
Consensus Conference (Table I) and a description of 
the vignettes. As the Dutch Blood Bank replaced male-
donor only plasma with solvent/detergent-treated plasma 
in 2015, all vignettes were designed with transfusion of 
standard red blood cell products, standard pooled platelet 
concentrates of five buffy coats in male-only plasma 
and solvent/detergent-treated plasma. All participants 
were sent up to four reminders if the survey had not 
been completed after which all uncompleted surveys 
were regarded as drop-outs. Reminders were sent out 
every 2 weeks.
Vignettes
We used vignettes to investigate which factors 
influenced the decision of attending physicians and 
haemovigilance staff to report a case of TRALI. A 
vignette is a brief, written case history of a fictitious 
patient based on a realistic clinical situation. The 
description is followed by a question to explore what a 
physician would do if presented with the actual patient. 
Factors, such as setting, patient's age, and disease, are 
varied in the vignette to investigate how these changes 
influence physicians' decision-making. To enhance 
comparability with our baseline study from 2008, we 
used the same factors for the vignettes23. These factors 
were selected based on observational, retrospective 
and prospective studies which indicated that higher 
patients' age, a severe underlying clinical disease, for 
example sepsis, multiple transfusions and the presence 
of a risk factor for ALI, are risk factors for developing 
TRALI13,15,22,24-28. Our previous study indicated that in the 
Dutch population these variables influenced the decision 
to report a suspected case of TRALI. We included these 
five factors and the time of onset of ALI after transfusion 
Table I - Definition of transfusion-related acute lung injury.
TRALI Acute onset within 6 hours of blood transfusion
PaO2/FIO2 <300 mmHg, or worsening of the PaO2 to FIO2 ratio
Bilateral infiltrative changes on chest radiograph
No sign of hydrostatic pulmonary oedema (pulmonary arterial occlusion pressure ≤18 mmHg or central venous pressure ≤15 mmHg)
No other risk factor for acute lung injury
Possible TRALI Same as for TRALI, but another risk factor present for acute lung injury
PaO2: partial pressure of oxygen in arterial blood; FIO2: fraction of inspired oxygen; TRALI: transfusion-related acute lung injury.
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as factors in the vignettes (Table II) to explore whether 
additional scientific evidence on TRALI pathogenesis 
has influenced how physicians report TRALI. A total of 
144 vignettes presented all possible combinations of the 
six factors and their (3×3×2×2×2×2) factor levels. The 
number of representative clinical vignettes was reduced 
to 16 using an orthogonal main effects design29. This 
approach enables statistical testing by conjoint analysis 
of a suitable fraction of all possible combinations of the 
factors and their levels. Respondents were asked to rate 
the degree to which they would consider reporting each 
of the 16 patients described in the clinical vignettes as 
suspected of having TRALI and initiating a diagnostic 
work-up for the condition. A seven-point Likert scale 
was used ranging from 1 (totally disagree) to 7 (totally 
agree) to answer the question: "Would you report this 
case as suspected TRALI?" (Table III). 
Determinants of transfusion-related acute lung 
injury
The third part of the survey included an additional 
ten questions on how patients' variables influenced the 
respondent's decision to suspect TRALI or an alternative 
diagnosis. We asked the respondents whether they took 
parameters of cardiac function, fluid balance, culture 
results and transfusion product metrics into account 
in their decision to report a suspected case of TRALI. 
These questions were rated on a scale from 0-100 in 
which 0 corresponded to "I do not take this factor into 
account in my diagnostic considerations in a suspected 
case of TRALI" and 100 with "I take this factor fully into 
account in my diagnostic considerations in a suspected 
case of TRALI". 
Statistical analysis
Conjoint analysis was performed to calculate the 
relative weights for each level of the factor levels. This 
results in a utility score (common unit) for each factor 
level, expressed as β with a 95% confidence interval 
between brackets. Higher utility values indicate greater 
preference. Negative β values indicate preferences 
against the positive direction of the statement, i.e. 
against reporting a case suspected of being TRALI. 
The utility for a particular factor level is determined by 
multiplying the β with the defined factor category, i.e., 
one times β, two times β, depending on the number of 
levels per factor. 
Data were inspected for normality. As none of the 
responses of the influence of factors on the decision-
making process to report TRALI followed a normal 
distribution, these factors were investigated with R 
using a Kruskal-Wallis test. If the Kruskal-Wallis test 
produced a p<0.05, a post-hoc Dunn test was performed. 
A p<0.05 was considered statistically significant. 
Table II - Factors incorporated in the clinical vignettes. 
Factor Level
Age of the patient 20 years
80 years
TRALI risk factor Sepsis
Ischaemic cerebrovascular accident
Onset of symptoms Within 2 hours after transfusion
Within 5 hours after transfusion
Type and amount of transfusion One red blood cell transfusion
One platelet transfusion
One S/D plasma transfusion
One red blood cell transfusion and one S/D plasma transfusion
Six red blood cell transfusions and four S/D plasma transfusions
ALI before transfusion Present
Absent
TRALI: transfusion-related acute lung injury; S/D: solvent/detergent; ALI: acute lung injury.
Table III - Example vignettes.
Vignette structure Vignette A Vignette B
A (1)-year old patient is treated in the ICU for (2). 
Within (3) hour(s) of transfusion of (4) the patient 
develops ALI. The patient had (5) ALI risk factor 
before transfusion.
A 20-year old patient is treated in the ICU for 
sepsis. Within 1 hour of transfusion of 1 unit of 
red blood cells and 1 unit S/D plasma the patient 
develops ALI. The patient had an ALI risk factor 
before transfusion.
An 80-year old patient is treated in the ICU for 
an ischaemic cerebrovascular accident. Within 1 
hour of transfusion of 1 unit of platelets the patient 
develops ALI. The patient had no ALI risk factor 
before transfusion.
Would you report this case as TRALI? Would you report this case as TRALI? Would you report this case as TRALI?
ICU: intensive care unit; TRALI: transfusion-related acute lung injury; S/D: solvent/detergent; ALI: acute lung injury.
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Conjoint analysis was performed in SPSS for Windows 
version 22.0 (IBM Corp., Armonk, NY, USA). R was 
used to produce figures with the most recent version 
of the ggplot2 package and to perform Kruskal-Wallis 
testing (R-core Team, Vienna, Austria).
Results
In total 173 heads of departments from 63 hospitals 
agreed to participate in our study. We sent out the 
online questionnaire to 38 intensive care physicians, 38 
anaesthesiologists, 19 haematologists, 22 transfusion 
physicians and 56 haemovigilance officers. Of the invited 
respondents, 31 intensive care physicians (81.6%), 26 
anaesthesiologists (68.4%), 19 haematologists (100%), 
43 haemovigilance officers (76.8%) and 10 transfusion 
medicine physicians (52.6%) returned the questionnaire, 
which amounted to a total of 129 responses (74%). One 
respondent did not fill in his specialisation. This response 
was included in the analysis of the vignettes but was 
excluded from the sub-analysis per speciality. Table IV 
summarises the demographic data of the respondents. 
Vignettes on reporting transfusion-related acute 
lung injury
Our analysis revealed that respondents were more 
likely to report TRALI in 20-year old patients developing 
lung injury than in 80-year old patients (b-coefficient 
0.26 [0.05-0.47]). Respondents were less likely to report 
a TRALI case if the patient was admitted with sepsis 
than if the patient was admitted with a cerebrovascular 
accident (b-coefficient –0.28 [–0.49 to –0.07]). Reporting 
of TRALI was also dependent on the time of onset of ALI 
symptoms. Participants were more likely to report the 
case if pulmonary deterioration occurred within 1 hour 
after transfusion than when symptoms occurred within 
5 hours (b-coefficient 0.41 [0.20-0.62]). The number 
and type of transfusion products modulated TRALI 
reporting. Transfusion of platelets or plasma increased 
the chance of reporting compared to transfusion of red 
blood cells (platelets: b-coefficient 0.15 [–0.08-0.39]; 
plasma: b-coefficient 0.08 [–0.08-0.24]). Respondents 
were most likely to report a TRALI case when multiple 
transfusion products were administered (b-coefficient 
0.31 [–0.09-0.71]). Finally, participants were less 
inclined to report patients who already had a risk factor 
for ALI (b-coefficient –0.98 [–0.77 to –1.19]). Figure 1 
illustrates the preferences for each variable. Sub-analysis 
of the response pattern per specialisation, sex, clinical 
vs non-clinical specialisation or work experience did not 
influence the results.
Questionnaires
Additional determinants that may influence reporting 
TRALI were measured on a scale of 0-100. Our results 
show that the 24-hour fluid balance, the presence of 
an ALI risk factor, and administration of multiple 
Table IV - Demographic characteristics of respondents. 
Intensive care 
physician*
Anaesthesiologist Haematologist Haemovigilance 
officer†
Transfusion 
medicine physician
N (% of total respondents) 31 (23.8) 26 (20.0) 23 (17.7) 39 (30.0) 10 (7.7)
Sex (%) Female 29 27 39 66 50
Age (%) <29 years 0 0 0 0 0
30-39 years 19.4 15.4 12.8 12.8 30
40-49 years 71 34.6 25.6 25.6 0
50-59 years 6.5 38.5 38.5 38.5 70
>60 years 3.2 11.5 23.1 23.1 0
Years of experience (%) 0-5 years 25.8 7.7 17.4 2.6 30
6-10 years 41.9 23.1 8.7 18.0 10
11-15 years 25.8 15.4 26.1 23.1 10
16-20 years 0 7.7 21.7 12.8 10
>21 years 6.5 46.2 26.1 41.0 40
Hospital (%) Academic 19.4 23.0 30.4 7.7 0
Non-academic 80.6 76.9 69.6 89.6 100
TRALI-cases reported last year 
(median with range) 0 (0-5) 0 (0-2) 1 (0-5) 0 (0-5) 0.5 (0-3)
The total of the percentages does not reach 100% in all columns because of missing responses from two respondents. *Of the total of 31 intensive care 
physicians, 18 originated from internal medicine, 12 from anaesthesiology and 1 from cardiology. †Of the total of 39 haemovigilance officers, 22 studied 
biomedical sciences, medicine or medical pharmacy and 14 were qualified laboratory analysts with additional haemovigilance training. Four respondents 
did not specify their training. TRALI: transfusion-related acute lung injury.
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Figure 1 - Preferences of respondents for determinants on reporting TRALI. A positive b-coefficient indicates a higher likelihood 
of reporting TRALI.
 TRALI: transfusion-related acute lung injury; CVA: cerebrovascular accident; RBC: red blood cells; PLT: platelets; FFP: 
fresh-frozen platelets; ALI: acute lung injury; 95% CI: 95% confidence interval.
transfusions products influence the decision to suspect 
TRALI. The storage time of the transfused product, on 
the other hand, has limited influence on the decision to 
report a case (Figure 2). Of note, however, intensivists 
and anaesthesiologists are more likely to take the storage 
time of transfused products into account than transfusion 
medicine physicians and haemovigilance officers 
(p<0.02). Additional analysis of the questionnaire per 
speciality shows that compared to the other specialists, 
haemovigilance staff are less likely to weigh parameters 
of cardiac performance in the decision to report, 
including systolic and diastolic ventricular function. 
Transfusion medicine physicians are more likely to 
take blood culture results into account than the other 
specialists (p<0.05). Haematologists, transfusion 
medicine physicians and haemovigilance officers are 
more likely to take the presence of an ALI risk factor 
into account than intensivists and anaesthesiologists 
(p<0.02; Figure 2). Overall, the clinical specialties 
are more focused on patient-related factors while the 
haemovigilance staff and transfusion specialists are more 
focused on transfusion-related factors in their differential 
diagnostic considerations on post-transfusion pulmonary 
complications (Figure 2).
Discussion
In this study we investigated the practice of 
reporting TRALI. The results of the present survey 
are strikingly similar to the findings of 8 years 
ago. The survey from 2008, which was conducted 
among intensive care physicians, haematologists, 
haemovigilance staff and transfusion medicine 
physicians in the Netherlands showed that the presence 
of an underlying condition, for example sepsis ("first 
hit"), was a reason for not reporting TRALI23. This 
indicated that reporting physicians notified TRALI 
according to the "single-hit" theory. Since 2008 several 
studies have been published that support the "two-hit" 
pathogenesis of TRALI13-22. There is also evidence 
supporting the concept that increasing severity of the 
"first hit" causes more severe TRALI for both the 
forms mediated by antibodies and those not mediated 
by antibodies16,17,22,30,31. Clinical studies have confirmed 
these findings and shown that patients with more severe 
underlying disease are at higher risk of developing 
lung injury after transfusion13,14,22,26. In this study we 
investigated whether the determinants that influence 
TRALI reporting have changed accordingly. However, 
our study demonstrates that the factors influencing 
reporting of TRALI are similar to those in 2008. The 
chance that the multidisciplinary team involved in 
TRALI reporting will designate a case as (possible) 
TRALI decreases in younger patients, decreases after 
transfusion of a single red blood cell, fresh-frozen 
plasma or platelet product, and decreases in patients 
with an additional ALI risk factor or sepsis - the patients 
most at risk of developing TRALI. In other words, 
respondents are still most likely to report "the young 
and fast" ALI-developers. 
There are several possible explanations for the 
observation that the tendency to report follows the 
"one-hit" theory and has not shifted to the "two-hit" 
model. It could indicate that physicians are unaware of 
the "two-hit" theory on TRALI. Possibly the disciplines 
involved in TRALI reporting do not realise that elderly 
patients, patients with an ALI factor, and patients with 
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more severe underlying disease, such as sepsis, are 
most at risk of developing TRALI14,32. However, it also 
possible, although this cannot be easily tested with 
vignettes, that physicians are unaware of a patient's 
medical history or are unable to evaluate the patient's 
medical history for the presence of a "two-hit" event 
resulting in TRALI. It may be particularly difficult for 
specialists involved in reporting, but who are not at the 
bedside, to gain insight into a patient's medical history. 
Another factor that might influence reporting is that 
the presentation of TRALI is similar to that of acute 
respiratory distress syndrome or pulmonary oedema, 
including transfusion-associated cardiac overload. 
The differential diagnosis for acute (worsening) lung 
injury is extensive, especially in patients with acute 
respiratory distress syndrome risk factors. This can result 
in the physician overlooking TRALI or deciding that 
another factor may have caused lung injury and not the 
transfusion. The Dutch haemovigilance system uses a 
TRALI score system including imputability of symptoms 
to the transfused blood product33. This can influence the 
decision to diagnose possible TRALI in patients with 
diseases presenting in a similar fashion not in line with 
the international consensus definition of TRALI.
Our results are consonant with those of studies 
in which TRALI and possible TRALI were under-
recognised and under-reported8,9,11,22,34-37. The under-
recognition of this condition has several implications: if 
TRALI in patients with more severe underlying disease 
or acute respiratory distress syndrome risk factors 
remains unrecognised, no immunological work-up will 
be performed at the hospital and/or blood bank and 
donors related to (possible) TRALI cases will no longer 
be excluded32. 
In the previous survey, plasma transfusion was the 
most influential factor for reporting TRALI. However, 
in our present follow-up study, plasma transfusion 
had almost no effect on the likelihood of respondents 
reporting a suspected case. We hypothesise that the 
implementation of male-only quarantine plasma in 2007 
and addition of male-only plasma to platelet concentrates 
in 2009 initiated a general understanding of the potential 
side-effects of transfusion and that implementation of 
these policies increased the realisation that the safety 
of plasma transfusion has increased in the past years. 
In 2014 quarantine plasma was replaced by solvent/
detergent-treated plasma nationwide, to further increase 
the safety of plasma transfusion. The reduction in the 
Figure 2 - Analysis by specialty of the influence of blood product and patient-related factors on the decision to suspect TRALI. 
 *, #, †, and ‡ = p<0.05. Haemovigilance officers were less likely than the other specialists to take ejection fraction into 
account. Haemovigilance officers and transfusion medicine physicians were more likely than the other specialists to take blood 
culture results into account. Intensivists and anaesthesiologists were more likely than transfusion medicine physicians and 
haemovigilance officers to take the storage time of transfused products into account. Haematologists, transfusion medicine 
physicians and haemovigilance officers were more likely than intensivists to take the presence of an ALI risk factor into 
account. LDH: lactate dehydrogenase; ALI: acute lung injury.
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effect of plasma transfusion on TRALI reporting in the 
vignettes may reflect the realisation that implementation 
of these new types of plasma - at least of male-only 
quarantine plasma - has reduced the incidence of 
TRALI38. 
The influence of some of the additional determinants 
that condition reporting of TRALI has changed between 
our two studies. The respondents' reported influence 
of echocardiographic estimation of cardiac function 
was graded similarly, but the 24-hour fluid balance 
and massive transfusion had more influence on the 
diagnostic considerations to report TRALI. This might 
reflect the enhanced focus on transfusion-associated 
cardiac overload in the recent years39. 
Our results lead us to speculate whether the 
disciplines familiarise themselves enough with each 
other's literature: on the one hand, anaesthesiologists 
and intensive care physicians tend to focus on patient-
related factors when they suspect TRALI, confirming 
the findings of a recent study in which clinical risk 
factors in recipients predominated in possible TRALI14. 
On the other hand, haematologists, haemovigilance 
officers and transfusion specialists are more focused on 
factors related to the transfusion products. Nevertheless, 
the storage time of transfusion products influenced 
the decision-making process considerably less than 
in the previous study. Storage of red blood cells has 
been implicated in transfusion-induced adverse events. 
However, in line with evidence from recent, large 
trials in which storage time of transfusion products 
was unrelated to transfusion-induced morbidity 
and mortality, the respondents take storage time of 
the transfusion products less into account in their 
diagnostic considerations40-42. Disciplines that are more 
closely in contact with the Dutch Blood Bank - the 
haemovigilance staff, haematologists and transfusion 
medicine physicians - seem to be most informed about 
the lack of evidence on storage time-mediated risk. Our 
results suggest that a number of intensive care medicine 
physicians and anaesthesiologists still believe that the 
age of the transfused products is related to transfusion 
complications. Hence, knowledge on patient-related 
risk factors on the one hand and transfusion-related risk 
factors for TRALI on the other hand may be limited to 
specialty areas in medicine and for this reason result in 
under-diagnosing and under-reporting. Integration of 
this knowledge in all disciplines involved in reporting 
TRALI may be warranted to increase the diagnosis and 
reporting of TRALI.
Our study has several limitations. Our overall 
response rate was good, but we were not able to reach 
all Dutch hospitals with at least five beds equipped for 
mechanical ventilation. However, we believe that the 
high rate of respondents of all disciplines from academic 
hospitals, large teaching hospitals and small regional 
hospitals ensures that our study results are representative 
of current TRALI reporting practice. 
Conclusions
As in previous studies, Dutch physicians tend to 
report TRALI according to a "one-hit" theory. Physicians 
refrain from reporting the "possible" two-hit TRALI in 
patients with additional pre-existent lung injury or other 
severe underlying disease. In this respect, a diagnosis of 
TRALI is withheld from patients with the highest risk 
of this severe transfusion-mediated complication. This 
suboptimal awareness hampers prophylactic treatment 
measures and identification and exclusion of relevant 
donors.
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